Hubert Köppler
University of Marburg
42 Papers
321 Citations
Hubert Köppler is an academic researcher from University of Marburg. The author has contributed to research in topics: Mitoxantrone & Rituximab. The author has an hindex of 14, co-authored 42 publications.
Chat about Author
Papers
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Rudolf Weide,Georg Hess,Hubert Köppler,Jochen Heymanns,Jörg Thomalla,Ali Aldaoud,Christoph Losem,Stefan Schmitz,Ursula Haak,Christoph Huber,Michael Unterhalt,Wolfgang Hiddemann,Martin Dreyling +12 more
TL;DR: BMR is a very effective new outpatient immuno-chemotherapy with low toxicity for patients with relapsed/refractory FL, MCL and other indolent lymphomas, and unexpected hospitalisations were necessary after 4% of BMR-application only.
99
Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
TL;DR: BMR is a well tolerated very effective outpatient treatment for relapsed and refractory CD20-positive indolent lymphomas and CLL and the time to next antilymphoma treatment is prolonged significantly by BMR.
70
Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review
Rudolf Weide,Hubert Köppler,L. Antras,M. A. Smith,Mph Eva Chang,Jesse Green,Neil Wintfeld,Maureen P. Neary,Mei Sheng Duh +8 more
TL;DR: It is suggested that multiple myeloma patients are more likely to experience renal impairment with zoledronic acid than with ibandronate, and the risk of renal impairment increased if patients had received prior therapy with zolingronic acid.
•Journal Article
Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas.
Rudolf Weide,Markus Tiemann,Karl-Heinz Pflüger,Hubert Köppler,B Parvizl,Hans-Heinrich Wacker,Hans Kreipe,Klaus Havemann,Mohammad R. Parwaresch +8 more
TL;DR: P105 expression is absent in 58% of high grade NHL, particularly in centroblastic and Burkitt's lymphomas, suggesting that inactivation of RB may play a crucial role in the pathogenesis of highgrade NHL.
45
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review
Ingo Diel,Rudolf Weide,Hubert Köppler,L. Antras,M. A. Smith,Jesse Green,Neil Wintfeld,Maureen P. Neary,Mei Sheng Duh +8 more
TL;DR: Patients were significantly more likely to experience renal impairment with zoledronic acid than with ibandronate, according to a retrospective review of German oncology clinics from May 2001 to March 2006.
41